These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37965265)

  • 1. Engineering a dual vaccine against COVID-19 and tuberculosis.
    Guthrie CM; Tan X; Meeker AC; Self AE; Liu L; Cheng Y
    Front Cell Infect Microbiol; 2023; 13():1273019. PubMed ID: 37965265
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Jia Q; Masleša-Galić S; Nava S; Horwitz MA
    mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
    Hart BE; Lee S
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005229. PubMed ID: 27941982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.
    Deng YH; He HY; Zhang BS
    J Microbiol Immunol Infect; 2014 Feb; 47(1):48-56. PubMed ID: 23357605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.
    Sali M; Di Sante G; Cascioferro A; Zumbo A; Nicolò C; Donà V; Rocca S; Procoli A; Morandi M; Ria F; Palù G; Fadda G; Manganelli R; Delogu G
    Infect Immun; 2010 Dec; 78(12):5202-13. PubMed ID: 20921146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.
    Tan K; Liang J; Teng X; Wang X; Zhang J; Yuan X; Fan X
    Hum Vaccin Immunother; 2014; 10(2):391-8. PubMed ID: 24192709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of BCG vaccine: a double-edged sword.
    Singh VK; Srivastava R; Srivastava BS
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):535-43. PubMed ID: 26810060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
    Chiwala G; Liu Z; Mugweru JN; Wang B; Khan SA; Bate PNN; Yusuf B; Hameed HMA; Fang C; Tan Y; Guan P; Hu J; Tan S; Liu J; Zhong N; Zhang T
    Biomed Pharmacother; 2021 Oct; 142():112047. PubMed ID: 34426260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.
    Mambelli F; Marinho FV; Andrade JM; de Araujo ACVSC; Abuna RPF; Fabri VMR; Santos BPO; da Silva JS; de Magalhães MTQ; Homan EJ; Leite LCC; Dias GBM; Heck N; Mendes DAGB; Mansur DS; Báfica A; Oliveira SC
    J Immunol; 2023 Jun; 210(12):1925-1937. PubMed ID: 37098890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
    Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
    Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immune responses to recombinant Mycobacterium bovis BCG constructs expressing major antigens of region of difference 1 of Mycobacterium tuberculosis.
    Shaban K; Amoudy HA; Mustafa AS
    Clin Vaccine Immunol; 2013 Aug; 20(8):1230-7. PubMed ID: 23761657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superinfection with SARS-CoV-2 Has Deleterious Effects on Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium tuberculosis.
    Hildebrand RE; Chandrasekar SS; Riel M; Touray BJB; Aschenbroich SA; Talaat AM
    Microbiol Spectr; 2022 Oct; 10(5):e0307522. PubMed ID: 36200898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?
    Gupta PK
    Cell Immunol; 2020 Oct; 356():104187. PubMed ID: 32745670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.